Customizable lyophilized agent for image-guided radiotherapy and drug delivery
AssigneeThe Johns Hopkins University
InventorsWilfred Ngwa, Michele Moreau
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a customizable lyophilized agent and its use for cancer treatment. The agent comprises a biocompatible lyophilized matrix and nanoparticles incorporated within the lyophilized matrix. The lyophilized matrix is reconstitutable with a biocompatible solvent to form a colloid. The nanoparticles provide imaging contrast for at least one imaging modality. The nanoparticles may provide contrast for both computed tomography and magnetic resonance imaging. The lyophilized matrix may be reconstituted with an aqueous solution of a therapeutic agent, allowing for customization of the agent for specific treatment needs.
Claims26
A customizable lyophilized agent, comprising:
- a biocompatible lyophilized matrix;
- and
- nanoparticles incorporated within the lyophilized matrix,
- wherein the lyophilized matrix is reconstitutable with a biocompatible solvent to form a colloid, and wherein the nanoparticles provide imaging contrast for at least one imaging modality.
(canceled)
A method of imaging a subject using a customizable lyophilized agent, comprising:
- reconstituting a lyophilized agent with a biocompatible solvent to form a colloid, wherein the lyophilized agent comprises a biocompatible lyophilized matrix and nanoparticles incorporated within the lyophilized matrix;
- administering the colloid to the subject;
- and
- imaging the subject using at least one imaging modality, wherein the nanoparticles provide imaging contrast for the at least one imaging modality.
(canceled)
16-19. (canceled)
25-29. (canceled)
A method of preparing a customizable lyophilized agent, comprising:
- mixing a biocompatible hydrogel with nanoparticles to form a mixture;
- freezing the mixture;
- and
- lyophilizing the frozen mixture to produce a lyophilized agent,
- wherein the lyophilized agent is reconstitutable with a biocompatible solvent to form a colloid, and wherein the nanoparticles provide imaging contrast for at least one imaging modality.
31-34. (canceled)
36-41. (canceled)
Dependencies are inferred from the claim text.